ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

LTRN Lantern Pharma Inc

5,23
-0,23 (-4,21%)
27 Apr 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Lantern Pharma Inc LTRN NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
-0,23 -4,21% 5,23 06:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
5,55 5,42 6,04 5,50 5,46
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
24.4.202414:00BWLantern Pharma Launches “Webinar Wednesdays” Featuring..
22.4.202414:12BWLantern Pharma Receives Regulatory Approval to Expand..
18.3.202421:02BWLantern Pharma Reports Fourth Quarter & Fiscal Year 2023..
18.3.202412:12IHMARKETNEWSAnticipation Builds on Wall Street for Federal Reserve’s..
15.3.202413:00BWLantern Pharma Announces Initial Patients Dosed in..
11.3.202412:30BWLantern Pharma to Report Fourth Quarter and Fiscal Year 2023..
05.3.202414:01BWLantern To Participate in H.C Wainwright & Co.’s (HCW) 1st..
04.3.202414:01BWLantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion..
01.3.202403:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15.2.202414:01BWLantern Pharma Advances Unique ADC (Antibody Drug Conjugate)..
19.1.202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17.1.202413:30BWStarlight Therapeutics, a Subsidiary of Lantern Pharma..
29.12.202322:05EDGAR2Form 8-K - Current report
01.12.202312:02EDGAR2Form SC 13D/A - General statement of acquisition of..
01.12.202312:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30.11.202314:00BWFDA Grants Lantern Pharma Orphan Drug Designation for Drug..
24.11.202322:05EDGAR2Form 8-K - Current report
08.11.202322:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08.11.202322:05EDGAR2Form 8-K - Current report
08.11.202322:01BWLantern Pharma Reports Third Quarter 2023 Financial Results..
01.11.202313:00BWLantern Pharma to Report Third Quarter 2023 Operating &..
20.10.202323:25EDGAR2Form 8-K - Current report
10.10.202314:00BWLantern Pharma to Present at the ThinkEquity Conference on..
03.10.202314:00BWLantern Pharma Announces Publication in Clinical Cancer..
25.9.202314:30BWLantern Pharma Announces First Patient Dosed in the Phase 1..
18.9.202315:00BWLantern Pharma Receives IND Clearance from FDA Enabling..
31.8.202314:00BWLantern Pharma to Present Data Highlighting the Anti-Tumor..
28.8.202314:00BWLantern Pharma Expands AI Capabilities of RADR® Platform to..
14.8.202314:30BWLantern Pharma Receives Notice of US Patent Allowance for..
09.8.202322:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09.8.202322:05EDGAR2Form 8-K - Current report
09.8.202322:01BWLantern Pharma Reports Second Quarter 2023 Financial Results..
02.8.202314:00BWLantern Pharma to Report Second Quarter 2023 Operating &..
17.7.202314:00BWLantern Pharma to Participate and Present at Multiple..
26.6.202314:30BWOncotarget Publishes New Data by Lantern Pharma, an AI..
12.6.202314:30BWLantern Pharma Receives FDA Clearance of IND Application for..
08.6.202315:00BWLantern Pharma Leverages AI Platform, RADR®, to Develop..
17.5.202314:00BWLantern Pharma to Present at the Lytham Partners Spring 2023..
09.5.202322:01BWLantern Pharma Reports First Quarter 2023 Financial Results..
03.5.202315:00PRNUSLantern Pharma Selects REPROCELL USA to Provide Support for..
02.5.202322:01BWLantern Pharma to Report First Quarter 2023 Operating &..
02.5.202313:30BWLantern Pharma Develops Top-Ranked AI Algorithms to Predict..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock